Pfizer's Pneumococcal Vaccine Could See a Boost in Sales After the CDC's Recommendation for Use in Older Adults

Pfizer’s Prevnar 13 Could See a $2 Billion Boost in Sales

Pfizer's Pneumococcal Vaccine Could See a Boost in Sales After the CDC's Recommendation for Use in Older Adults

Pfizer’s Pneumococcal Vaccine Could See a Boost in Sales After the CDC’s Recommendation for Use in Older Adults

On Wednesday, Pfizer announced that the CDC’s Advisory Committee on Immunisation Practices (ACIP) has decided to recommend and promote the Prevnar 13 pneumococcal vaccine for use in adults aged 65 and up. The vaccine protects against pneumococcal diseases including pneumonia, which can be caused by any of the 13 pneumococcla serotypes which are included in the vaccine and give it its name.

The CDC recommends that adults aged 65 and up, who have never received a pneumococcal vaccine in the past, should receive a dose of Prevnar 13, and in addition, should receive a dose of PPSV23 afterwards.  Even if someone in this group has received a PPSV23 vaccine in the past, but not Prevnar 13, they should receive a dose of Prevnar 13.

These recommendations will be reviewed and evaluated in 2018, at which point it is expected that vaccine sales will fall due the development of herd immunity . Approximately 900,000 Americans contract pneumococcal pneumonia each year, and this places a huge strain on health are services and government spending.

Read more about it here: Advisory Committee on Immunization Practices Votes to Recommend Pfizer’s Prevnar 13® Vaccine in Adults Aged 65 Years and Older

Leave a Reply

Your email address will not be published. Required fields are marked *